文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

冠心病风险:低密度脂蛋白及其他。

Coronary heart disease risk: Low-density lipoprotein and beyond.

机构信息

Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, MD, USA.

Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, MD, USA; Community Hospital General Medical Center, Sterling, IL, USA.

出版信息

Trends Cardiovasc Med. 2022 May;32(4):181-194. doi: 10.1016/j.tcm.2021.04.002. Epub 2021 Apr 17.


DOI:10.1016/j.tcm.2021.04.002
PMID:33872757
Abstract

Coronary heart disease (CHD) is the leading cause of morbidity and mortality world-wide and has been characterized as a chronic immunoinflammatory, fibroproliferative disease fueled by lipids. Great advances have been made in elucidating the complex mechanistic interactions among risk factors associated with CHD, yielding abundant success towards preventive measures and the development of pharmaceuticals to prevent and treat CHD via attenuation of lipoprotein-mediated risk. However, significant residual risk remains. Several potentially modifiable CHD risk factors ostensibly contributing to this residual risk have since come to the fore, including systemic inflammation, diabetes mellitus, high-density lipoprotein, plasma triglycerides (TG) and remnant lipoproteins (RLP), lipoprotein(a) (Lp[a]), and vascular endothelial dysfunction (ED). Herein, we summarize the body of evidence implicating each of these risk factors in residual CHD risk.

摘要

冠心病(CHD)是全球发病率和死亡率的主要原因,其特征为慢性免疫炎症、纤维增生性疾病,由脂质引发。在阐明与 CHD 相关的危险因素之间复杂的机制相互作用方面取得了巨大进展,通过减轻脂蛋白介导的风险,为预防措施和开发预防和治疗 CHD 的药物带来了丰富的成功。然而,仍然存在显著的剩余风险。一些潜在可改变的 CHD 危险因素显然促成了这种剩余风险,包括全身炎症、糖尿病、高密度脂蛋白、血浆甘油三酯(TG)和残余脂蛋白(RLP)、脂蛋白(a)(Lp[a])和血管内皮功能障碍(ED)。在此,我们总结了这些危险因素中每一个在残余 CHD 风险中的作用的证据。

相似文献

[1]
Coronary heart disease risk: Low-density lipoprotein and beyond.

Trends Cardiovasc Med. 2022-5

[2]
Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies.

J Am Heart Assoc. 2016-4-29

[3]
Assessment of Remnant Lipoprotein Cholesterol and Oxidized Low density Lipoprotein Associated with Low-grade Inflammation in Coronary Heart Disease Subjects of Young South Indian Population.

J Assoc Physicians India. 2022-6

[4]
A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with type 1 (insulin-dependent) diabetes mellitus.

Diabetes Res Clin Pract. 1992-12

[5]
Serum high density lipoprotein cholesterol levels in Chinese healthy subjects and patients with certain diseases.

Atherosclerosis. 1982-6

[6]
Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.

Circulation. 2001-9-4

[7]
Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study.

Atherosclerosis. 2002-8

[8]
Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein(a) as risk factors for coronary heart disease.

Med Clin North Am. 1994-1

[9]
Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects.

Am J Cardiol. 2002-10-1

[10]
Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women.

J Am Coll Cardiol. 2009-12-29

引用本文的文献

[1]
The systemic inflammatory response index as a risk factor for all-cause and cardiovascular mortality among individuals with coronary artery disease: evidence from the cohort study of NHANES 1999-2018.

J Geriatr Cardiol. 2025-7-28

[2]
Effect of puerarin administration on serum NOD-like receptor protein 3 (NLRP3) inflammasome, C1Q/TNF-related protein 3 (CTRP3) and lipoprotein-associated phospholipase 2 (LP-PLA2) levels.

J Med Biochem. 2025-6-13

[3]
Serum albumin combined with high-density lipoprotein cholesterol as a novel marker to predict coronary heart disease: are their associations multiplicative or rateable?

Front Cardiovasc Med. 2025-7-30

[4]
Histone deacetylase 4: A therapeutic target for cardiovascular diseases (Review).

Int J Mol Med. 2025-10

[5]
Combining echocardiography with carotid ultrasound parameters in predicting major adverse cardiovascular events among older individuals with coronary artery disease.

PeerJ. 2025-7-23

[6]
Non-traditional lipid biomarkers in atherosclerotic cardiovascular disease: pathophysiological mechanisms and strategies to address residual risk.

Front Endocrinol (Lausanne). 2025-7-10

[7]
Association of C reactive protein triglyceride glucose index with mortality in coronary heart disease and type 2 diabetes from NHANES data.

Sci Rep. 2025-7-9

[8]
Overview of systematic reviews on Chinese patented oral medicines for promoting blood circulation and removing blood stasis combined with western medicine in the treatment of coronary heart disease angina pectoris.

Front Cardiovasc Med. 2025-6-20

[9]
Relationship between dynamic changes in remnant cholesterol and cardiovascular disease in middle-aged and older Chinese: a national cohort study.

Front Cardiovasc Med. 2025-6-19

[10]
Interpretable machine learning analysis of immunoinflammatory biomarkers for predicting CHD among NAFLD patients.

Cardiovasc Diabetol. 2025-7-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索